UK consumer healthcare firm Haleon announced yesterday it finalized the acquisition of the remaining 12% stake it did not yet own in Tianjin TSKF Pharmaceutical from its partner Tianjin Pharmaceutical Da Ren Tang Group, gaining full control of its OTC JV in China.